Provided by Tiger Trade Technology Pte. Ltd.

Kura Oncology

11.20
-0.1000-0.88%
Pre-market: 11.270.0700+0.63%05:02 EDT
Volume:1.79M
Turnover:20.25M
Market Cap:994.27M
PE:-3.33
High:11.52
Open:11.31
Low:11.14
Close:11.30
52wk High:13.90
52wk Low:7.36
Shares:88.77M
Float Shares:70.60M
Volume Ratio:0.95
T/O Rate:2.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3668
EPS(LYR):-3.1784
ROE:-167.71%
ROA:-31.30%
PB:20.53
PE(LYR):-3.52

Loading ...

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 04

Kura Oncology, Kyowa Kirin dose first patient in Japan Phase 2 ziftomenib trial

Reuters
·
Apr 28

H.C. Wainwright Reaffirms Their Buy Rating on Kura Oncology (KURA)

TIPRANKS
·
Apr 20

Barclays Sticks to Their Buy Rating for Kura Oncology (KURA)

TIPRANKS
·
Apr 20

Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating

TIPRANKS
·
Apr 18

Sector Update: Health Care Stocks Higher Pre-Bell Friday

MT Newswires Live
·
Apr 17

BUZZ-Kura Oncology rises as kidney cancer combo shows early promise

Reuters
·
Apr 17

Kura says darlifarnib-cabozantinib trial posts 44% response rate in pretreated ccRCC

Reuters
·
Apr 17

Kura Oncology Inc - Reports Manageable Safety and Tolerability Profile in Rcc Patients

THOMSON REUTERS
·
Apr 17

Kura Oncology Inc - Treatment Durations Reached 56 Weeks; One-Third Remained on Therapy at Data Cut-off

THOMSON REUTERS
·
Apr 17

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

THOMSON REUTERS
·
Apr 17

Kura Oncology Initiated at Buy by Lake Street

Dow Jones
·
Apr 14

Kura Oncology announces annual shareholder meeting via webcast

Reuters
·
Apr 11

Kura Oncology to present FIT-001 darlifarnib-cabozantinib data in pretreated kidney cancer

Reuters
·
Apr 09

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

GlobeNewswire
·
Apr 09

Kura Oncology grants inducement stock options for 153,750 shares under 2023 plan

Reuters
·
Apr 03

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 03

Kura Oncology Inc : Mizuho Cuts Target Price to $25 From $30

THOMSON REUTERS
·
Mar 25

Kura Oncology Is Maintained at Outperform by Mizuho

Dow Jones
·
Mar 25

Kura Oncology price target lowered to $25 from $30 at Mizuho

TIPRANKS
·
Mar 24